>
产品中心 >
Small_molecule >
Medchemexpress/Reparixin(Synonyms: Repertaxin; DF 1681Y)/HY-15251/10mg
CustomerValidation
- •AnnRheumDis.2016Apr;75(4):730-8.
- •NatCommun.2017May26;8:15584.
- •CellDeathDis.2017Jul13;8(7):e2932.
- •StemCells.2015Dec;33(12):3558-68.
- •BiochimBiophysActa.2017Jan;1863(1):220-230.
- •Oncotarget.2017Jul21;8(36):60210-60222.
- •Oncogenesis.2016Jun13;5(6):e234.
- •JGastroenterolHepatol.2017May8.
- •VetImmunolImmunopathol.2016Dec;182:52-58.
Description | ReparixinisapotentinhibitorofbothCXCL8receptorsCXCR1/2,itinhibitsweaklyCXCR2-mediatedcellmigration(IC50=100nM),whereasitstronglyblocksCXCR1-mediatedchemotaxis(IC50=1nM). |
---|---|
IC50&Target | IC50:5.6/80nM(CXCR1wt/CXCR1Ile43Val,inL1.2cell)[1] |
InVitro | ReparixinisapotentfunctionalinhibitorofCXCL8-inducedBIOLOGicalactivitiesonhumanPMNswithamarkedselectivity(around400-fold)forCXCR1,asshowninspecificexperimentsonCXCR1/L1.2andCXCR2/L1.2transfectedcellsandonhumanPMNs.TheefficacyofReparixinissignificantlylowerinL1.2cellsexpressingIle43ValCXCR1mutant(IC50valuesof5.6nMand80nMforCXCR1wtandCXCR1Ile43Val,respectively)[1].Reparixinisanon-competitiveallostericinhibitorofIL-8receptorswitha400-foldhigherefficacyininhibitingCXCR1activitythanCXCR2[2]. |
InVivo | ReparixinisaninhibitorofCXCL8receptorCXCR1andCXCR2activation,hasbeenshowntoattenuateinflammatoryresponsesinvariousinjurymodels.Spontaneouslyhypertensiverats(SHR)areadmiNISTeredasubcutaneousinjectionofReparixin(5mg/kg)dailyfor3weeks.Reparixineffectivelydecreasessystolicbloodpressureandincreasedthebloodflow[3].ReparixinreducesthelevelsofIL-1βinthebrainaftermiddlecerebralarteryocclusion/reperfusion(MCAo)inmice.BarsrepresentlevelsofIL-1β(pg/100mg)measuredbyELISAinthebraintissuesofmicesubjectedornot(SHAM)toMCAoandpretreatedwithvehicleorReparixin(30mg/kg,s.c.)[4]. |
References |
|
PreparingStockSolutions |
Pleaserefertothesolubilityinformationtoselecttheappropriatesolvent. | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CellAssay [1] | Reparixinisdissolvedinsalineattheappropriatedilution[1]. L1.2CellsUSPension(1.5-3×106cells/mL)isincubatedat37°Cfor15mininthepresenceofvehicleorofReparixin(1nM-1μM)andnextseededintriplicatesintheuppercompartmentofthechemotacticchamber.Differentagonistsareseededinthelowercompartmentofthechamberatthefollowingconcentrations:1nMCXCL8,0.03nMfMLP,10nMCXCL1,2.5nMCCL2,30nMC5a.Thechemotacticchamberisincubatedat37°Cinairwith5%CO2for45min(humanPMNs)or2h(monocytes).Attheendofincubation,thefilterisremoved,fixed,andstainedandfiveoilimmersionfieldsathighmagnification(100×)arecountedforeachmigrationwellaftersamplecoding.L1.2migrationisevaluatedusing5μmporesizeTranswellfilters[1].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. | ||||||||||||||||
AnimalAdministration [3][4] | Reparixinisdissolvedinsalineandadministeredsubcutaneously(MiceandRat). Rat[3] | ||||||||||||||||
References |
|
MolecularWeight | 283.39 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Formula | C₁₄H₂₁NO₃S | ||||||||||||
CASNo. | 266359-83-5 | ||||||||||||
Storage |
| ||||||||||||
Shipping | RoomtemperatureincontinentalUS;mayvaryelsewhere | ||||||||||||
Solvent&Solubility | DMSO:≥500mg/mL Reparixinisprepareinvehicle(sterilesaline)[5]. *"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">1> | ||||||||||||
References |
|
Purity:99.88%ee.:100.00%